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 INTRODUCTION 
 Plasmodium falciparum malaria is a leading cause of mor-
tality in tropical countries, with most of the deaths occurring in 
children from sub-Saharan Africa. 1– 3 As resistance to available 
antimalarial drugs worsens, morbidity and mortality rises as a 
direct consequence. 4 In 2006 the World Health Organization 
(WHO) recommended the use of artemisinin-based combina-
tion therapy (ACT) as the first-line treatment of uncompli-
cated  P. falciparum malaria in all endemic areas because of 
its efficacy and potential to reduce the spread of drug resis-
tance. 5 The ACTs are currently the most preferred treatments 
for uncomplicated falciparum malaria, and many sub-Saharan 
African countries have already implemented ACTs as first 
line treatments. 4, 6– 9 
 Artesunate-mefloquine is an ACT, which has been widely 
used in Asia; but also in Africa this combination appears to be 
highly efficacious in patients with uncomplicated  P. falciparum 
malaria. 4, 10 The recommended treatment is 4 mg/kg body 
weight of artesunate given once a day for 3 days and 25 mg/kg 
of mefloquine split over 2 or 3 days. 5 Recently, a novel fixed-
dose pediatric co-formulation of artesunate and mefloquine 
(Artequin Pediatric, Mepha, Switzerland) was developed. 
This stickpack formulation (i.e., a thin, tube-shaped foil pack) 
contains mango-flavored artesunate (50 mg) and mefloquine 
(125 mg) in separate granules, which may be administered 
directly into the mouth of the patient. It is a further devel-
opment of the co-blister tablet preparation (Artequin), which 
proved to be highly efficacious and well tolerated in patients 
from Southeast Asia 11 and Africa 12– 16 when given for 3 days. In 
a pharmacokinetic study in pediatric patients, the fixed-dose 
pediatric formulation and the standard co-blister of artesu-
nate-mefloquine delivered comparable systemic exposure to 
the active moieties dihydroartemisinin and mefloquine. 17 
 Because of insufficient safety and tolerability data for arte-
sunate-mefloquine, there has been concern regarding the use 
of this combination in African children, which restricted its 
deployment in this setting. 5, 10 One reason for this data gap is 
the lack of an appropriate pediatric formulation. 18 Another 
reason is the concern that artesunate-mefloquine may be 
poorly tolerated by young children, although it has been previ-
ously suggested that children tolerate ACTs as well as or even 
better than adults. 4 In some malaria treatment trials, meflo-
quine monotherapy caused a higher rate of certain gastroin-
testinal (GI) and central nervous system (CNS) adverse events 
(AEs) compared with chloroquine (dizziness), halofantrine 
(nausea, vomiting, fatigue, dizziness) and artemether-lumefan-
trine (nausea, vomiting, dizziness, insomnia). 19 In particular, 
the potential neuropsychiatric effects of mefloquine attracted 
attention in the past. 20– 22 Likewise, when mefloquine was com-
bined with an artemisinin derivative to treat malaria, dizzi-
ness was commonly reported by adults from Southeast Asia; 
however, it was generally not considered clinically relevant 
or caused by the underlying malaria disease. 23, 24 In African 
adults, dizziness was less likely to occur when mefloquine 
was combined with artesunate compared with mefloquine 
monotherapy. 25 
 Concerns have also been raised by preclinical observations 
of neurotoxicity with artemisinin derivatives. In animal stud-
ies, intramuscular oil-based artemether and arteether have 
been associated with neuronal damage, particularly in areas of 
the brainstem involved in hearing and gait control 7 ; however, 
the findings have never been confirmed in humans. 
 Against this background, the safety and efficacy of the 
new granule formulation of artesunate-mefloquine was 
investigated in young African children with uncomplicated 
 P. falciparum malaria. The primary aim was to assess the neu-
ropsychiatric safety of the new pediatric formulation. Major 
secondary outcomes included Day-28 and Day-63 polymerase 
chain reaction (PCR)-corrected cure rates. 
 METHODS 
 Study site.  The study was performed between December 
2007 and March 2009 in Yaoundé, Cameroon, where malaria 
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transmission is intense and perennial. 26 Patients with 
microscopically confirmed acute uncomplicated  P. falciparum 
malaria were recruited from the peri-urban area of Yaoundé. 
 Study population.  Male or female children presenting 
with signs and symptoms of malaria were screened for study 
eligibility. Inclusion criteria were body weight between 10 and 
20 kg, fever (temperature ≥ 37.5°C axillary or ≥ 38°C orally, 
rectally or tympanically) or history of fever in the preceding 
24 hours,  P. falciparum malaria with a density between 
2,000/μL (amended to 1,000/μL) and 250,000/μL blood, ability 
to take drugs by mouth and to comply with the study protocol, 
and provision of written informed consent by the parent or 
guardian. Exclusion criteria included presence of severe and 
complicated malaria (e.g., cerebral malaria) as defined by 
WHO, 27 history of serious side effects related to artesunate-
mefloquine or similar drugs, use of antimalarial drugs or any 
other agent with antimalarial activity within the previous 
week, ingestion of mefloquine within the previous 30 days, 
serious underlying disease, presence of severe vomiting or 
diarrhea, history of epilepsy, convulsion or splenectomy, and 
need for parenteral treatment. 
 Before enrollment, written informed consent was obtained 
from the parents or legal guardians of the child. The trial proto-
col was approved by the National Ethics Committee, Yaoundé, 
Cameroon and the Ethics Committee of the Technical Uni-
versity of Dresden, Medical Faculty, Germany. This study is 
registered with ClinicalTrials.gov as NCT00978172. 
 Study design and procedures.  This was an open-label, single-
center, single-arm study. Patients were enrolled consecutively 
and admitted to the health facility for the first day of a 3-day 
treatment phase, and then followed up until Day 63 after 
treatment. A follow-up period of 63 days complied with the 
WHO guideline from 2003 recommending this observation 
period for patients treated with artesunate-mefloquine to 
avoid an underestimation of recrudescence rates. 28 Those 
patients recruited between December 2007 and June 2008 
( N = 50) were included in a prospectively planned interim 
analysis. The data from these patients were reviewed by 
an independent malaria expert and a neuropediatrician to 
confirm or reassess the initially planned sample size of 600 
patients, and to look for insufficient efficacy and potential 
safety issues. 
 The investigational therapy (Artequin Pediatric) con-
sisted of artesunate 50 mg/day (2.5–5 mg/kg/day) and meflo-
quine 125 mg/day (6.25–12.5 mg/kg/day) given in equal oral 
doses simultaneously in a fixed-dose formulation (stickpack 
with a mixture of artesunate and mefloquine granules) once 
daily for 3 consecutive days. The entire content of one stick-
pack was directly administered on the child’s tongue. In case 
of administration difficulties, the content was to be put on a 
spoon and administered with a small amount of liquid. The 
mouth was thereafter to be rinsed with some liquid, e.g., with 
milk or water, and remaining granules swallowed. Patients 
have been encouraged to resume normal food intake as soon 
as food could be tolerated. The first dose was administered 
under supervised conditions at the health facility. The second 
and third doses were given at home by the parent or guard-
ian. The two stickpacks for administration at home had to be 
returned to the study site (used or not) to check for treatment 
compliance. Patients who vomited a dose within 30 minutes 
after intake received a full replacement dose. No more than 
one dose was to be replaced per day. The study medication 
was provided by Mepha Ltd., Aesch, Switzerland in Good 
Manufacturing Practice quality. 
 Parents or guardians were asked to bring their children 
back to the health center on Days 4, 7, 28, and 63 or on any 
other day if the child did not feel well. Rescue therapy accord-
ing to local practice was administered to patients with early or 
late treatment failures, 28 new falciparum infection, and in case 
of vomiting the study replacement dose. In case of premature 
discontinuation of study medication, information on the status 
of the patient was collected according to the scheduled study 
visits. Vital signs and hematology parameters were assessed 
at baseline and each follow-up visit. At baseline and at every 
follow-up visit, potential AEs were assessed for severity and 
association with study medication. 
 Neuropsychiatric examinations took place at baseline and 
on Days 7, 28, and 63. These examinations included standard-
ized questions (in local language) to the parent or guard-
ian concerning their observations, questions to the children 
according to their age and development status, doctor’s obser-
vations, and standardized neurological assessments. 29– 32 Apart 
from neurological abnormalities, the neuropsychiatric exami-
nation included an anamnesis/questionnaire looking for sleep-
ing disorders, neurocognitive and behavioral disturbances, 
speech disturbances, and eating disturbances. All neuropsychi-
atric symptoms that occurred newly or worsened from base-
line were recorded as AEs or serious adverse events (SAEs), 
independent whether elicited through the structured ques-
tionnaire or spontaneously reported by the patient or parent/
guardian. 
 Giemsa-stained thick and thin blood films were examined 
before initiation of treatment and at every follow-up visit 
(scheduled or not). Blood films were considered negative if 
no parasites were seen in 100 oil-immersion fields in a thick 
blood film. The thin film was used for species determination. 
Two qualified microscopists independently read the slides. In 
case of discrepant results, slides were additionally read by a 
parasitologist. 
 To distinguish between recrudescence and new infection, 
blood samples for PCR analysis were collected from every 
patient at baseline and on Days 4, 7, 28, and 63. Additional 
PCR samples were taken in case the patient spontaneously 
returned to the health unit for signs and symptoms of malaria. 
For PCR analysis, a common technical protocol was used. 33 
 Discussion of study design.  An open-label, non-comparative 
design was adopted as done previously with ACTs in this 
vulnerable population. 34, 35 At the time of the study, no suitable 
pediatric formulation of an ACT was available (i.e., approved by 
regulatory authorities), which could have acted as comparator. 
In addition, it was expected that clinical judgment can be 
applied to assess the clinical relevance of the rate of occurrence 
of neuropsychiatric events, the primary aim of the trial. 
Neuropsychiatric AEs were assessed in a way appropriate for 
children, according to their age and developmental status with 
a standardized questionnaire and examination. The study lasted 
for 63 days, which represents three half-lives of mefloquine. 36 
 Study endpoints.  The primary objective of the trial was to 
assess the neuropsychiatric safety of the pediatric granule 
formulation of artesunate-mefloquine based on the incidence 
of neuropsychiatric AEs. Efficacy outcomes represented 
secondary study endpoints. Therapeutic outcomes were clas-
sified according to the current WHO protocol (WHO 2003) 
and included the proportion of patients who showed an 
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adequate clinical and parasitological response (ACPR) at 28 
and 63 days (PCR corrected and uncorrected). The ACPR 
was defined as absence of parasitemia on Day 28 (or Day 
63) irrespective of axillary temperature, without any previous 
occurrence of early treatment failure, late clinical failure, or 
late parasitological failure. 
 Statistical analysis.  A conservative 40% rate of neurop-
sychiatric AEs was assumed for the study treatment based on 
AE frequencies (mainly dizziness) reported for mefloquine 
when the drug was combined with an artemisinin deriva-
tive in adults from Southeast Asia. 23, 24 With a study size of 
600 patients, the two-sided 95% confidence interval (CI) was 
estimated to be approximately 36–44% when the observed rate 
would actually be 40%. An interim analysis was prospectively 
planned to confirm or reassess the initially planned sample 
size. On the basis of this interim analysis ( N = 50), the study 
size was reduced from 600 to 200 patients because of the low 
incidence of neuropsychiatric AEs overall and the virtual 
absence of drug-related neuropsychiatric AEs. 
 This was a single-arm study; hence, no pre-defined statis-
tical hypothesis was tested. Consequently, no adjustment for 
multiple testing was made and two-sided 95% CIs were cal-
culated for the primary safety variable (i.e., neuropsychiat-
ric AEs). Day-28 and Day-63 ACPR rates were analyzed by 
the Kaplan-Meier method. 28 Patients who discontinued study 
participation without fulfilling the criteria of early treat-
ment failure, late clinical failure, or late parasitological failure 
(e.g., losses to follow-up), or to whom another antimalarial 
drug was administered without fulfilling these criteria were 
considered censored at the time of withdrawal/start of rescue 
antimalarial medication. For analysis of the PCR-corrected 
rates, re-infections were additionally classified as censored 
observations in the Kaplan-Meier analysis. 
 Data were analyzed on the basis of different populations. 
The analysis of the primary safety endpoint was based on a 
modified safety population, defined as all patients who took 
at least one dose of study medication and had a post-baseline 
neuropsychiatric assessment on Day 7 or who reported a drug-
related neuropsychiatric AE at any time before a new malaria 
episode occurred. The safety population included all patients 
who received at least one dose of study drug and had at least 
one post-baseline assessment, regardless of whether sched-
uled or unscheduled. A modified intention-to-treat (ITT) pop-
ulation was used for analyzing ACPR rates, and comprised all 
patients who had positive parasitemia at baseline and took at 
least one dose of study medication. Patients who discontin-
ued the study before Day 4 without previous occurrence of 
early treatment failure or who had a mixed strain infection 
(as assessed by PCR) were excluded. 
 RESULTS 
 In total, 220 patients with uncomplicated falciparum malaria 
were enrolled; 83.6% of patients completed the 63-day study 
( Table 1 ). Main reasons for patients discontinuing the study 
prematurely were loss to follow-up and the presence of a new 
malaria episode. The 3-day treatment period was completed 
by 96.8% of patients ( N = 213), and 38.9% of the patients 
(14 of 36) who prematurely discontinued the study participa-
tion did so at or after Day 28. Only two patients discontinued 
the study because of an AE (severe malaria and convulsions), 
both occurred during the 3-day treatment period but were 
considered unrelated to the study drug. Most patients (197 
of 220, 89.5%) adhered to the visit schedule throughout the 
study, and only a low proportion of patients (< 1%) returned 
unused stickpacks to the study site. The mean (range) actual 
antimalarial doses in mg/kg/day were 3.5 (2.5–5) for artesu-
nate and 8.8 (6.25–12.5) for mefloquine. 
 For both, the modified safety population and the modified 
ITT population, 213 (96.8%) participants qualified for inclu-
sion. The main reason for exclusion was missing follow-up 
data for any visit (2.3%). In total, 215 (97.7%) patients were 
included in the safety population. Baseline demographics 
and background characteristics are shown in  Table 2 . There 
was a balanced gender distribution. Approximately half of 
the patients were 1.5–3.5 years of age with an overall mean 
of 3.2 years (median: 3.1 years). The age ranged between 
8 months and 8 years; five patients were younger than 1 year. 
Mean parasite density was 36,476/μL (median: 20,040/μL). 
Most common malaria symptoms at baseline were fatigue 
(84.5% of patients), anorexia (70.4%), fever (60.6%), and ane-
mia (46.5%). Vomiting at baseline was observed in 24.9% of 
patients. The study population recruited represented the tar-
get population in countries where malaria is endemic. 
 Table 1 
 Patient disposition (enrolled patients) 
 N = 220 n (%)
Completed 63-day study 184 (83.6)
Discontinued study before Day 63 36 (16.4)
Adverse event 2 (0.9)
Lost to follow-up 16 (7.3)
Moved from study area 1 (0.5)
New episode of malaria 12 (5.5)
Subject withdrew consent 3 (1.4)
Protocol violation 2 (0.9)
 Table 2 
 Baseline demographics and background characteristics of patients * 
 N = 213
Sex n (%)
Male 104 (48.8)
Female 109 (51.2)
Race n (%)
African 213 (100)
Mean age (yr) 3.2
SD 1.5
Range 0.7–7.9
Mean weight (kg) 14.2
SD 2.8
Range 10–20
Age categories n (%)
< 1.5 years 27 (12.7)
≥ 1.5 to < 3.5 years 104 (48.8)
≥ 3.5 to < 5 years 51 (23.9)
≥ 5 years 31 (14.6)
Mean height (cm)  N = 212 
94.8
SD 11.5
Range 72–123
Mean parasite density, asexual forms (/μL) 36,476
SD 43,593
Range 1,000–248,800
 *  For modified safety population (i.e., all patients who took at least one dose of study 
medication and had a post-baseline neuropsychiatric assessment on Day 7 or who reported 
a drug-related neuropsychiatric adverse event at any time before a new malaria episode 
occurred). 
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 Tolerability and safety.  Artesunate-mefloquine was well 
tolerated by the study participants. Only two children vomited 
during the 3-day treatment period. One patient vomited the 
study drug and the replacement dose on Day 1, another patient 
vomited the Day-2 study medication. 
 In total, 28 patients reported 50 neuropsychiatric AEs over 
the study course ( Table 3 ), which represented 13.0% (95% 
CI: 9.0 to 18.0%) of the safety population and 13.1% (95% 
CI: 8.9 to 18.4%) of the modified safety population. All these 
AEs were newly emerging. The most frequent neuropsychi-
atric AE was sleeplessness/insomnia, which was reported for 
7.0% of patients, followed by altered eating behavior (4.7%) 
and headache (3.7%); 35 of 50 neuropsychiatric AEs started 
≥ Day 10, 30 of 50 ≥ Day 20, and 25 of 50 ≥ Day 30. In the 
majority of cases, these AEs lasted for 3–6 days. There was no 
marked difference between the different age groups in terms 
of incidence rates ( Table 3 ). It appeared that very young chil-
dren were less frequently affected but the number of patients 
with assessments was low ( N = 27). Almost all of the neurop-
sychiatric AEs were either mild or moderate in severity. One 
child suffered from severe convulsion, which was considered 
unrelated to study medication and caused by the underlying 
malaria disease. The event resolved within 2 days on treatment 
with intravenous quinine. 
 The incidences of drug-related neuropsychiatric AEs (pri-
mary safety variable) are shown in  Table 3 . Out of the 50 neu-
ropsychiatric AEs, 11 were suspected to be study drug-related 
and occurred in 8 patients. This represented 3.7% (95% 
CI: 2.0 to 7.0%) of the safety population and 3.8% (95% CI: 1.6 
to 7.3%) of the modified safety population. The most frequent 
drug-related neuropsychiatric AE was sleeplessness/insomnia, 
which was reported in 4 (1.9%) patients. In addition, single 
episodes of dizziness, headache, vertigo, nightmares, hyperac-
tivity, aggressive behavior, and altered eating behavior were 
reported. Most of these drug-related AEs started within the 
first 10 days of the study and usually lasted for 4 to 7 days; all 
of them showed a spontaneous resolution. There was no dif-
ference between the different age groups in terms of incidence 
rates. All drug-related neuropsychiatric AEs were of mild to 
moderate severity. 
 A total of 169 AEs other than neuropsychiatric were 
reported in 112 patients (52.1%). The most frequently affected 
system organ classes were infections and infestations (27.0%) 
and blood and lymphatic system disorders (20.5%). The most 
frequent AEs were anemia (20.5%), bronchitis (7.0%), and 
pyrexia (6.5%); vomiting was reported by 4 (1.9%) patients. 
Most of these AEs were either mild or moderate in severity. 
The AEs were not unexpected in children suffering from acute 
uncomplicated malaria and were largely pre-existing at base-
line. Eleven [reported in 10 (4.7%) patients] of the 169 non-
CNS AEs were classified as related to the study drug. All of 
the AEs suspected to be drug-related were mild or moderate 
in severity. The most frequent drug-related AEs were anemia 
(6 patients, 2.8%), diarrhea (2 patients, 0.9%) and vomiting 
(2 patients, 0.9%); they all had an onset within the first week of 
the study and lasted for 1–3 days, except anemia, which lasted 
3–4 weeks. 
 Overall, six SAEs occurred in 5 (2.3%) patients. One patient 
suffered from two episodes of anemia requiring hospitaliza-
tion. Both episodes occurred in the context of a malaria infec-
tion. Two patients were hospitalized for severe malaria in the 
context of re-infections, one child was hospitalized because of 
severe asthenia related to the baseline malaria infection, and 
one patient suffered from convulsions during the night after 
baseline assessment and was hospitalized. All six SAEs were 
classified as not related to the study drug and resolved by the 
time of the last follow-up visit. No patient died. 
 Changes of vital signs and hematology parameters were in 
accordance with malaria recovery. 
 Efficacy.  Cure rates were high ( Table 4 ). The PCR-corrected 
ACPR rates were 96.6% for both Day 28 and Day 63 (Kaplan-
Meier analysis). Simple proportions of PCR-corrected 28-day 
and 63-day ACPR rates for evaluable patients were 96.5% (194 
of 201) and 96.0% (168 of 175), respectively. In one patient, 
parasitemia was present at Day 15 but no PCR result was 
available. This patient was classified as having a recrudescence. 
Three other patients revealed a PCR-confirmed recrudescence 
on Days 26, 11, and 18, respectively. All four recrudescences 
were associated with typical signs and symptoms of malaria, 
and were therefore classified as late clinical failures. Three 
patients (1.4%) were classified as early treatment failures. 
One patient vomited the study drug and the replacement 
dose at Day 1. Another presented with convulsions during the 
night after baseline, and was treated with intravenous quinine. 
Finally, one child developed severe malaria and was also 
treated with intravenous quinine. In a conservative approach, 
these three patients with early treatment failure were classified 
as recrudescences. No patient developed late parasitological 
failure. 
 In the non-PCR corrected analysis, the ACPR rates were 
96.1% for Day 28 and 85.4% for Day 63 (Kaplan-Meier 
analysis). There were 22 patients with a PCR-confirmed new 
 Table 3 
 Patients with at least one neuropsychiatric adverse event * 
All neuropsychiatric AEs 
n/ N (%) [95% CI]
Drug-related neuropsychiatric AEs 
n/ N (%) [95% CI]
Total 28/213 (13.1) 
[8.9 to 18.4]
8/213 (3.8) 
[1.6 to 7.3]
< 1.5 years 2/27 (7.4) 
[0.9 to 24.3]
1/27 (3.7) 
[0.1 to 19.0]
≥ 1.5 to < 3.5 years 15/104 (14.4) 
[8.3 to 22.7]
4/104 (3.9) 
[1.1 to 9.6]
≥ 3.5 to < 5 years 6/51 (11.8) 
[4.4 to 23.9]
2/51 (3.9) 
[0.5 to 13.5]
≥ 5 years 5/31 (16.1) 
[5.5 to 33.7]
1/31 (3.2) 
[0.1 to 16.7]
 * For modified safety population (i.e., all patients who took at least one dose of study medi-
cation and had a post-baseline neuropsychiatric assessment on Day 7 or who reported a drug-
related neuropsychiatric AE at any time before a new malaria episode occurred). 
 AE = adverse event; CI = confidence interval. 
 Table 4 
 Proportion of patients with ACPR * 
Kaplan Meier estimate 95% CI
ACPR-PCR corrected (%)
Day 28 96.6 93.0 to 98.4
Day 63 96.6 93.0 to 98.4
ACPR-uncorrected (%)
Day 28 96.1 92.4 to 98.0
Day 63 85.4 79.7 to 89.7
 *  For modified intention-to-treat population (i.e., all patients who had positive parasitemia 
at baseline and took at least one dose of study medication; patients who discontinued the 
study before Day 4 without previous occurrence of early treatment failure or who had a 
mixed strain infection were excluded). 
 ACPR = adequate clinical and parasitological response; CI = confidence interval; PCR 
corrected = polymerase chain reaction method was used to exclude new  P. falciparum infec-
tions from this analysis. 
1038 TIETCHE AND OTHERS
 P. falciparum infection up to Day 63 (11.2% of 197 evaluable 
patients). Mean time to re-infection was 52 ± 11 days (median: 
56 days); there was only one re-infection by Day 28. The most 
frequently used rescue medication for treatment failure or new 
infection was artemether/lumefantrine (3.3% of patients). 
 DISCUSSION 
 The assessment of the safety and efficacy of a new pediat-
ric granule formulation of artesunate-mefloquine in the treat-
ment of uncomplicated falciparum malaria in African children 
weighing 10–20 kg was the main purpose of this study. The 
new formulation was well tolerated and highly efficacious in 
the treatment of falciparum malaria in young Cameroonian 
children. Very few patients (3.8%) reported drug-related neu-
ropsychiatric AEs out of which sleeplessness/insomnia of mild 
to moderate severity occurred most frequently. All non-drug-
related neuropsychiatric events were likely to be related to the 
underlying malaria disease. Only 4.7% of patients reported 
non-CNS AEs suspected to be drug-related, all of mild or 
moderate severity; mainly anemia and gastrointestinal disor-
ders, which also may have been attributable to the underly-
ing malaria infection. Non-drug-related, non-CNS AEs were 
observed but all of them were expected in children suffer-
ing from acute uncomplicated malaria and were largely pre-
existing at baseline. No new safety signal was detected. 
 Data on neuropsychiatric effects of mefloquine in young 
children are limited. One study performed in Southeast Asia 
found no evidence for such effects in children less than 5 years 
of age (weighing > 5 kg), when mefloquine, either alone or 
combined with an artemisinin derivative, was administered to 
treat falciparum or vivax malaria. 37 In a recent study, neither 
artesunate nor mefloquine resulted in significant impairment 
of behavior or motor function in Karen children, aged between 
3 months and 5 years, when compared with non-febrile con-
trols. 38 Our study in young African children confirmed these 
findings. We observed a low incidence of neuropsychiatric 
AEs; none represented a safety concern. In addition, the study 
corroborated the absence of clinically relevant neurotoxic 
effects caused by oral artemisinin derivatives in general and 
artesunate in particular. 39, 40 However, the number of African 
children treated with artesunate-mefloquine is still relatively 
small, and the occurrence of rare and potentially severe AEs 
cannot be completely ruled out. 
 Vomiting of antimalarial drugs is an important consider-
ation in treatment. Mefloquine may cause two types of vom-
iting: early vomiting (< 1 hour after intake) related to gastric 
intolerability and late vomiting (> 1 hour and up to Day 7) 
probably related to central effects and co-existence of dis-
ease-related symptoms. 41 In this study, vomiting occurred in 
4 (1.9%) patients, with only two children vomiting early. This 
low proportion is in agreement with previous studies in adoles-
cents and adults from Africa using the artesunate-mefloquine 
co-blister preparation. 12, 13, 15, 16 The other types of reported AEs 
also were comparable to the ones that have been described in 
African patients using the co-blister, 12– 16 and were most com-
monly symptoms of malaria. Likewise, the pattern of changes 
seen in clinical laboratory parameters was consistent with 
acute malaria and its resolution. 
 As expected, the efficacy of the new artesunate-mefloquine 
pediatric formulation was excellent, with PCR-corrected 
ACPR rates of 96.6% for both Day 28 and Day 63, thereby 
indicating the absence of recrudescence after Day 28. In ado-
lescents and adults, high Day-28 cure rates have been pre-
viously reported for the artesunate-mefloquine co-blister 
preparation. 12– 16 In one study, a Day-42 ACPR rate of 100% 
was shown in a small subgroup of patients. 14 Short observa-
tion periods may yield an underestimation of recrudescence 
rates. Hence, we chose a long follow-up period of 63 days, 
which deserves special attention. The high PCR-adjusted cure 
rate over 63 days suggests a sustained efficacy with artesunate-
mefloquine in young African children, possibly caused by the 
long half-life of mefloquine; although undetected, transient 
recrudescences between Days 28 and 63 could have occurred. 
The results were in accordance with those of a large study pre-
viously published: van Vugt and colleagues 42 reported a Day-
63 PCR-adjusted cure rate of 94% in patients from Southeast 
Asia. In a more recent study in the same population, a lower 
Day-63 PCR-corrected success rate was observed with arte-
sunate-mefloquine (approximately 90%), which may reflect 
a decreased sensitivity to mefloquine in Southeast Asia or 
chance fluctuations. 43 
 It has been suggested that ACT partner drugs with longer 
prophylactic times could result in a larger impact in higher-
transmission settings, although their long-term benefit must 
be evaluated in relation to the risk of parasite resistance. 44 
In this context, the re-infection rates observed in our study 
appear of interest. Only 11% of evaluable patients showed a 
re-infection at 63 days, which is remarkably low in high malaria 
transmission areas. In a recent large, randomized study in 
East African children (Tanzania), the effectiveness of amodi-
aquine ( N = 270), amodiaquine+sulfadoxine-pyrimethamine 
( N = 507), amodiaquine+artesunate ( N = 515), and artemether-
lumefantrine ( N = 519) was compared. 45 Re-infection rates 
at Day 28 were 28%, 27%, 31%, and 18%, respectively, and 
thus markedly higher than in this study, which lasted 5 weeks 
longer. In West Africa, an unadjusted 42-day risk of treat-
ment failure of 12.2% for dihydroartemisinin-piperaquine 
was reported in children < 5 years of age from Burkina Faso. 46 
Our results confirm the expected prevention of re-infection 
by mefloquine over a prolonged period of time, comparable to 
that of dihydroartemisinin-piperaquine. 
 The administration of study medication was largely done 
under non-supervised conditions (i.e., the administration 
of two of the three drugs took place at home). This is close 
to normal outpatient practice. The limitations of the study 
included the absence of an active control arm, which makes 
it difficult to estimate relative safety and efficacy in compari-
son with other treatments. In addition, it was an open-label 
study, which is associated with the unavoidable risk of bias, 
particularly with regard to AE reporting. However, the use of 
a standardized questionnaire adapted according to age and 
developmental status, and the conduct of standardized neu-
rological examinations lowered the risk of bias. Moreover, the 
fact that neuropsychiatric AEs were elicited (not only sponta-
neously reported) carried the risk for over-reporting of such 
AEs; whereas certain signs and symptoms, which are difficult 
to assess in very young children (e.g., dizziness), may have 
been under-reported in this age group. 
 In conclusion, over a 2-month observation period, the new 
fixed-dose pediatric granule formulation of artesunate-meflo-
quine administered once daily for 3 consecutive days was well 
tolerated and highly efficacious for the treatment of acute 
uncomplicated  P. falciparum malaria in young Cameroonian 
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children weighing between 10 and 20 kg. A small proportion of 
patients reported drug-related neuropsychiatric AEs of which 
sleeplessness/insomnia occurred most frequently. Despite 
earlier restrictions, there seems to be no reason to withhold 
artesunate-mefloquine from this population. 
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